ワシントンにおける肺がんの臨床試験
ワシントン内の拠点で、肺がんに関する43件の研究が参加者を募集しています。
ワシントン内の都市
公式研究テキスト（英語）
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Valley Medical Center, Renton
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT04267848The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Washington, Fred Hutchinson Cancer Center, Seattle
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Providence Regional Cancer System-Aberdeen, Aberdeen
- PeaceHealth Saint Joseph Medical Center, Bellingham
- Providence Regional Cancer System-Centralia, Centralia
- 他19件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Swedish Cancer Institute-Edmonds, Edmonds
- Swedish Cancer Institute-Issaquah, Issaquah
- Swedish Medical Center-First Hill, Seattle
被験者募集中第3相
70歳以上 · 全性別 · 2026/10/01更新 · NCT06096844Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Kadlec Clinic Hematology and Oncology, Kennewick
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT04181060Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06625775Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Swedish Cancer Institute-Edmonds, Edmonds
- Swedish Cancer Institute-Issaquah, Issaquah
- Swedish Medical Center-First Hill, Seattle
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06498635Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- University of Washington - Fred Hutchinson Cancer Center, Seattle
- Compass Oncology, Vancouver
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT06765109Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Northwest Cancer Specialists, P.C., Vancouver
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07222566A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Vista Oncology Inc PS, Olympia
被験者募集中第3相
18歳〜100歳 · 全性別 · 2026/09/25更新 · NCT05920356This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- American Oncology Network Vista Oncology Division-West office, Olympia
- American Oncology Network Vista Oncology Division-East office, Olympia
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06758401A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Swedish Medical Center, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT06618287A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07063745Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, Edmonds
- Research Site, Seattle
被験者募集中第2相
18歳〜95歳 · 全性別 · 2026/09/23更新 · NCT05061550Tailored Patient Navigation to Improve the Uptake of Lung Cancer Screening in Tribal Communities in Western Washington State, SACRED LUNGS Trial
- Muckleshoot Tribal Clinic, Auburn
- South Puget Intertribal Planning Agency (SPIPA), Shelton
被験者募集中健康なボランティア歓迎
18歳以上 · 全性別 · 2026/09/21更新 · NCT07176000A Restorative Justice-Based Lung Cancer Screening Decision-Making Support Intervention Tailored for Black Individuals to Increase Lung Cancer Screening Among Black Community Members, RESTORE Trial
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中健康なボランティア歓迎
50歳〜77歳 · 全性別 · 2026/09/17更新 · NCT07490860Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Fred Hutchinson Cancer Research Center, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT05786924A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Swedish Cancer Institute - Edmonds, Edmonds
- Kadlec Clinic Hematology and Oncology, Kennewick
- Swedish Medical Center, Seattle
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06119581AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Seattle
被験者募集中第1/2相
18歳〜75歳 · 全性別 · 2026/09/04更新 · NCT07038343Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
- Fred Hutchinson Cancer Center, Seattle
- Northwest Medical Specialties, Tacoma
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06343402The Vanguard Study: Testing a New Way to Screen for Cancer
- Madigan Army Medical Center, Tacoma
被験者募集中健康なボランティア歓迎
45歳〜75歳 · 全性別 · 2026/09/02更新 · NCT06995898Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Swedish Cancer Institute, Edmonds
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/01更新 · NCT07185997SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/31更新 · NCT07322341Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- Virginia Mason Medical Center, Seattle
- Legacy Cancer Institute Medical Oncology and Day Treatment, Vancouver
- Legacy Salmon Creek Hospital, Vancouver
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05624996Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/14更新 · NCT06518057PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中
18歳以上 · 全性別 · 2026/08/06更新 · NCT04151940Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/05更新 · NCT07444814Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- Xencor Investigative Site, Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/03更新 · NCT05433142Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/22更新 · NCT05098210A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- Fred Hutch Cancer Center, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/15更新 · NCT05652686Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- Fred Hutchinson Cancer Research Center, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/30更新 · NCT06162221Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
- Seattle Cancer Care Alliance, Seattle
被験者募集中第2相
18歳〜70歳 · 全性別 · 2026/06/26更新 · NCT04614103SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中第2相
18歳以上 · 全性別 · 2026/06/17更新 · NCT05570825A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/12更新 · NCT06051695Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- FHCC Overlake, Bellevue
- FHCC at EvergreenHealth, Kirkland
- Valley Medical Center, Renton
- 他4件
被験者募集中第2相
18歳以上 · 全性別 · 2026/06/03更新 · NCT05642572MYLUNG Consortium Part 3: Observational Study
- Northwest Cancer Specialists, P.C., Vancouver
被験者募集中観察研究
18歳以上 · 全性別 · 2026/05/18更新 · NCT05885698Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Virginia Mason Medical Center, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/05/15更新 · NCT05379985Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Swedish Cancer Institute-Edmonds, Edmonds
- Swedish Cancer Institute-Issaquah, Issaquah
- Swedish Medical Center-First Hill, Seattle
被験者募集中第2相
18 Minutes · 全性別 · 2026/05/05更新 · NCT06031688A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Virginia Mason Medical Center, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/22更新 · NCT07020221A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/13更新 · NCT06778863ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。